drugset / Trial / NCT01155284
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
Sanford Research/USD proposes to study the combination therapy of oral administration of sitagliptin and lansoprazole versus placebo for the preservation of pancreatic beta cells still present in patients with recent-onset diabetes and possibly regenerating their beta cells, while safely down-regulating the autoimmune response directed against the beta cells.
Timeline
- Start
- 2010-08
- Primary completion
- 2014-05
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lansoprazole | Other / unclassified | 30 mg | Oral |
| Subject | Lansoprazole | Other / unclassified | 60 mg | Oral |
| Subject | Sitagliptin | Small molecule | 50 mg | Oral |
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |